Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia

NCT00607373 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Lipid Metabolism, Inborn Errors
Hypercholesterolemia, Autosomal Dominant
Hyperlipidemias
Metabolic Diseases
Hyperlipoproteinemia Type II
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Metabolic Disorder
Congenital Abnormalities
Hypercholesterolemia
Hyperlipoproteinemias
Dyslipidemias
Lipid Metabolism Disorders

Interventions

DRUG: mipomersen
DRUG: Placebo

Sponsor

Kastle Therapeutics, LLC

Collaborators

[object Object]